Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Ethics Reg Allows Trade Group Pay; Top Staff Given Divestment Deadline

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health's revised ethics reg permits employee remuneration from trade groups and professional societies, though consulting agreements with pharma/biotech firms remain off limits

You may also be interested in...



People In Brief

Zerhouni leaving NIH: National Institutes of Health Director Elias Zerhouni will leave his post at the end of October to pursue other opportunities, according to a Sept. 24 letter to NIH staff. He says he is "extremely fortunate to have led the agency that has been at the center of" a biomedical science revolution, "one that continues to have broad and profound implications for human health." Zerhouni says he will work with Health and Human Services Secretary Mike Leavitt to appoint his successor at NIH. A same-day NIH release details Zerhouni's achievements since his confirmation as director in 2002, including establishing ethics regulations to address outside consulting by NIH employees and starting public health research initiatives, such as the NIH Obesity Research Task Force (1"The Tan Sheet" May 6, 2002, In Brief and 2"The Tan Sheet" Aug. 29, 2005, p. 11)

People In Brief

Zerhouni leaving NIH: National Institutes of Health Director Elias Zerhouni will leave his post at the end of October to pursue other opportunities, according to a Sept. 24 letter to NIH staff. He says he is "extremely fortunate to have led the agency that has been at the center of" a biomedical science revolution, "one that continues to have broad and profound implications for human health." Zerhouni says he will work with Health and Human Services Secretary Mike Leavitt to appoint his successor at NIH. A same-day NIH release details Zerhouni's achievements since his confirmation as director in 2002, including establishing ethics regulations to address outside consulting by NIH employees and starting public health research initiatives, such as the NIH Obesity Research Task Force (1"The Tan Sheet" May 6, 2002, In Brief and 2"The Tan Sheet" Aug. 29, 2005, p. 11)

People In Brief

Zerhouni leaving NIH: National Institutes of Health Director Elias Zerhouni will leave his post at the end of October to pursue other opportunities, according to a Sept. 24 letter to NIH staff. He says he is "extremely fortunate to have led the agency that has been at the center of" a biomedical science revolution, "one that continues to have broad and profound implications for human health." Zerhouni says he will work with Health and Human Services Secretary Mike Leavitt to appoint his successor at NIH. A same-day NIH release details Zerhouni's achievements since his confirmation as director in 2002, including establishing ethics regulations to address outside consulting by NIH employees and starting public health research initiatives, such as the NIH Obesity Research Task Force (1"The Tan Sheet" May 6, 2002, In Brief and 2"The Tan Sheet" Aug. 29, 2005, p. 11)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel